SynVaccine ⚠ Under review

Under review — some data on this profile may be inaccurate and is being re-verified.

SynVaccine develops vaccines based on synthetic biology, utilizing a CAD/CAM platform for designing and fabricating designer viruses for biotechnology.

Health Tech & Life Sciences
Active
Seed Tel Aviv-Yafo, Israel Founded 2013
Website ↗
Last updated 2026-07-26
Total raised
$1.8M
Last: Undisclosed Round 2017-11
Stage
Seed
Founded
2013
Headcount
6
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

SynVaccine is an Israeli startup that develops vaccines based on synthetic biology. The company has developed a proprietary technology that identifies significant parts of viruses and designs vaccines containing these components to elicit an immune response while excluding hazardous elements. Their technology enables the design and fabrication of viral genomes using a safety-focused approach, aiming to overcome limitations of naturally occurring viruses or those developed through traditional methods. SynVaccine's approach combines synthetic biology, virology, bioinformatics, engineering, and robotics to create novel vaccines and potentially cancer immunotherapies. The company was founded based on commercialized research from Tel Aviv University and Weizmann Institute of Science, led by Prof. Tamir Tuller.

Funding history · 2 rounds · $1.8M total

2017-10
Seed $1.7M
★ RAD BioMed★ Nava Zisapel★ Pix Vine Capital★ A2Z Venture Partners★ Yehuda Zisapel (Late)★ Sapir Venture Partners
2017-05
Grant $56K

Q&A

What is SynVaccine's primary focus?
SynVaccine develops vaccines based on synthetic biology, utilizing a CAD/CAM platform for designing and fabricating designer viruses for biotechnology.
When was SynVaccine founded?
SynVaccine was founded in July 2013.
What is SynVaccine's employee count?
SynVaccine has 1-10 employees.
What is the total amount of funding SynVaccine has raised to date?
SynVaccine has raised a total of $2,057,320 USD.
When did SynVaccine last raise a Seed round?
SynVaccine raised a Seed round in November 2017, securing $1,700,000 USD.
What is the most recent funding event for SynVaccine?
SynVaccine had a Secondary Round in June 2025.
Who are the co-founders of SynVaccine?
The co-founders of SynVaccine are Tamir Tuller and Tuval Ben Yehezkel.
What is SynVaccine's primary sector?
SynVaccine's primary sector is Health Tech & Life Sciences.

Team · 2

Tamir Tuller
Founder · Co-founder, Chief Scientist
Tuval Ben Yehezkel
Founder · Co-founder, Chief Scientist

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B

Highlights

1 Patents

Tags

pharmaceuticalsviral-diseasesbioinformaticsvaccines-developmentdisease-managementgenomicsanimal-healthlaboratoriesvaccinesbioconvergence
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitesynvaccine.com

Identifiers & details

Founded2013-7
Employees (exact)6

Radar intelligence

Patents

EPO4

Publications (Crossref)

Works3

Web history (Wayback)

Domainsynvaccine.com

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)514942291
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2013-07-02
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2026
Active charges / liens0
Registry events1 — annual_report (1)
Registered addressגולדה מאיר 3 נס ציונה

Recent registry events

DateEvent
2026-06-15דו~ח שנתי